SYNG Pharmaceuticals is developing a new first-in-class endometriosis test and non-hormonal therapy.
Focus: Therapeutics Commencement date: June 1, 2016 Location:JLABS @ Toronto
Endometriosis affects one in ten women of reproductive age and is characterized by debilitating menstrual pain, discomfort during intercourse, abnormal vaginal
bleeding, chronic pelvic pain and infertility. Despite being one of the most prevalent female reproductive disorders, it remains misdiagnosed, misunderstood and ineffectively treated. Often years can pass before a diagnosis is confirmed through laparoscopic surgery. Current treatments are problematic; hormone-based therapies have significant side effects and are not completely effective.
SYNG Pharma is developing a new first-in-class blood-based in-vitro diagnostic test and non-hormonal therapy for endometriosis.
Endometriosis is a significant unmet need which effects approximately 176 million women worldwide and half of them may face infertility. Women dear to me have had endometriosis, uterine fibroids, PCOS or infertility. As a scientist and an entrepreneur, I am committed to changing face of women health.